Skip to main content

Blood-brain barrier delivery technology

Blood-brain barrier
This PoC project aims to experimentally and commercially validate a novel, annexin-based method for carrying therapeutic molecules into the brain.

Over 98% of known drug molecules are unable to enter the brain, rendering a broad range of CNS diseases untreatable by traditional pharmacological mechanisms. Neurodegenerative diseases, brain cancer and mechanical- or hypoxia-induced brain trauma remain areas of enormous unmet clinical need; and a mechanism which could successfully carry drugs – which would otherwise be unable to cross the BBB – into the brain at relevant concentrations could provide enormous patient benefit, and have material commercial prospects.

This PoC project aims to experimentally and commercially validate a novel, annexin-based method for carrying therapeutic molecules into the brain.